Using Antibodies to Detect HIV Persistence in Treatment Intensification and Eradication Studies
Dr. S. Keating presented the following poster at CROI 2014 earlier this year.
Quantifying the degree of HIV persistence during therapy is difficult because of low viral load and integration of virus into cells. An alternative or complementary approach is to measure antibody responses to HIV. HIV incidence assays have been developed to measure antibody evolution during HIV seroconversion and can be used to investigate the association between HIV antibody levels, avidity and HIV antigen specificities in diverse cohorts of treated and untreated adults. This same principle can be used to measure the quality and quantity of antibodies as surrogate markers of HIV viral presence and decline during treatment intensification and eradication studies.